药用辅料对细胞色素P450氧化酶的作用研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (1): 99-102.

药用辅料对细胞色素P450氧化酶的作用研究进展

欧阳冬生^1,2, 帅放文², 周宏灏¹

¹中南大学临床药理研究所,遗传药理学湖南省重点实验室,长沙 410078,湖南;
²湖南省药用辅料工程技术研究中心,浏阳 410300,湖南

收稿日期:2012-06-05 修回日期:2012-06-05 发布日期:2013-02-05
通讯作者: 周宏灏,通信作者,男,教授,中国工程院院士。
作者简介:欧阳冬生,男,教授,博士生导师,研究方向:遗传药代动力学。 Tel: 0731-84805380 E-mail: ouyangyj@163.com
基金资助:
“重大新药创制”科技重大专项“十二五”实施计划项目(2012ZX09303014001)

Research progress on pharmaceutical necessities affecting the cytochrome P450

OUYANG Dong-Sheng^1,2, SHUAI Fang-Wen², ZHOU Hong-Hao¹

¹Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China;
²Hunan Pharmaceutical Necessities Engineering Technology Research Center, Liuyang 410300, Hunan, China

Received:2012-06-05 Revised:2012-06-05 Published:2013-02-05

摘要/Abstract

摘要： 药用辅料可显著影响药物代谢酶(CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A4)的活性,进而影响药物的代谢、疗效和安全性。药用辅料的生物学效应研究应引起重视。本文查阅了国内外发表的相关文献,进行了分析、综合。

关键词: 细胞色素P450酶, 药用辅料, 相互作用

Abstract: Pharmaceutical necessities could affect the activity of cytochrome P450 enzyme(CYP1A2,CYP2C9,CYP2C19,CYP2D6 and CYP3A4) and further influence drug metabolism, efficacy and safety. The biological effect research of pharmaceutical necessities should be taken seriously. This paper summarizes the research progress through reading lots of domestic and overseas relative literatures carrying on the analysis and comprehensive.

Key words: Cytochrome P450, Pharmaceutical necessities, Interaction

中图分类号:

R968

欧阳冬生, 帅放文, 周宏灏. 药用辅料对细胞色素P450氧化酶的作用研究进展[J]. 中国临床药理学与治疗学, 2013, 18(1): 99-102.

OUYANG Dong-Sheng, SHUAI Fang-Wen, ZHOU Hong-Hao. Research progress on pharmaceutical necessities affecting the cytochrome P450[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 99-102.

参考文献

[1] 国际药用辅料协会辅料成分指南[S].2009.
[2] 王艳. 新药研究中辅料的使用原则和申报要求[J]. 安徽医药, 2005, 9(10) : 785.
[3] Bittner B, Mountfield RJ.Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters[J]. Curr Opin Drug Discov Dev, 2002, 5(1):59-71.
[4] Liu Y, Huang L, Liu F.Paclitaxel nanocrystals for overcoming multidrug resistance in cancer[J]. Mol Pharma, 2010, 7(3):863-869.
[5] Buggins TR, Dickinson PA, Taylor G.The effects of pharmaceutical excipients on drug disposition[J]. Adv Drug Deliv Rev, 2007, 59(15):1482-1503.
[6] Goole J, Lindley DJ, Roth W, et al.The effects of excipients on transporter mediated absorption[J]. Int J Pharm, 2010, 393(1/2):17-31.
[7] 周宏灏,主编.新编遗传药理学[M].北京:人民军医出版社, 2011.
[8] Smith NF, Mani S, Schuetz EG,et al.Induction of CYP3A4 by Vinblastine: role of the nuclear receptor NR1I2[J]. Ann Pharmacother, 2010, 44(11):1709-1717.
[9] Shahzadi A, Javed I, Aslam B, et al.Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers[J]. Pak J Pharm Sci, 2011, 24(1):63-68.
[10] Park JY, Kim KA, Kim SL, et al.Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes[J]. Antimicrob Agents Chemother, 2003, 47(11):3464-3469.
[11] Ishikawa M, Yoshii H, Furuta T.Interaction of modified cyclodextrins with cytochrome P-450[J]. Biosci Biotechnol Biochem, 2005, 69(1):246-248.
[12] Zhu S, Huang R, Hong M, et al.Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450[J]. Eur J Pharm Sci, 2009, 37(5):573-580.
[13] Ren X, Mao X, Cao L, et al.Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo[J]. Eur J Pharm Sci, 2009, 36(4/5):401-411.
[14] Richard J. Mountfield, Sandrine Senepin, Michael Schleimer, et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450[J]. Int J Pharm, 2000, 211(1/2):89-92.
[15] Ren XH, Si LQ, Cao L,et al.Effect of polyoxylether analogous surfactants on the activity of cytochromes P450 3A in rats in vivo[J]. Acta Phar maceutica Sinica, 2008, 439(50): 528-534.
[16] Ren X, Mao X, Si L, et al.Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration[J]. Eur J Pharm Biopharm, 2008, 70(1):279-288.
[17] Bravo González RC, Huwyler J, Boess F, et al.In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam[J]. Biopharm Drug Dispos, 2004, 25(1): 37-49.
[18] Tompkins L, Lynch C, Haidar S, et al.Effects of commonly used excipients on the expression of CYP3A4 in Colon and liver cells[J]. Pharm Res, 2010, 27(8):1703-1712.
[19] Mudra DR, Borchardt RT.Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism[J]. J Pharm Sci, 2010, 99(2): 1016-1027.
[20] Wandel C, Kim RB, Stein CM.“Inactive” excipients such as cremophor can affect in vivo drug disposition[J]. Clin Pharmacol Ther, 2003, 73(5): 394-396.
[21] Bittner B, González RC, Isel H, et al.Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats[J]. Eur J Pharm Biopharm, 2003, 56(1):143-146.
[22] Bittner B, González RC, Walter I, et al.Impact of solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats[J]. Biopharm Drug Dispos, 2003, 24(4): 173-181.
[23] Lee YS, Kim YW, Kim SG, et al.Impact of poloxamers on kinetics of CYP3A in rat liver microsome[J]. Eur Neuropsychopharmacol, 2012,22(6):431-440.
[24] Johnson BM, Charman WN, Porter CJ.An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine[J]. AAPS PharmSci, 2002, 4(4):E40.
[25] Ren XH, Si LQ, Cao Lei, et al.Effect of two different doses of PEG400 with multiple administration on the activity of cytochrome P450 3As in rat[J]. Chin Hosp Pharm J, 2008, 28(22):1912-1916.